- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03627338
Medication Adherence in Patients With Liver Cirrhosis
Medikamentenadhärenz Bei Patientinnen Und Patienten Mit Leberzirrhose
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objective of the study is to investigate drug adherence in cirrhotic patients and to gain a better understanding of the causes of deficient adherence including evaluation for medication beliefs, satisfaction, depression, anxiety and health-related quality of life. A number of long-term medications have been approved for this group of patients in various indications and / or recommended by guidelines. However, adherence has not been adequately investigated yet. The investigators aim to focus on the following groups of ingredients / classes:
- Primary and secondary antibiotic prophylaxis (e.g. Norfloxacin)
- Non-selective beta-blockers (e.g. Carvedilol and Propranolol)
- diuretics (Spirolactones [e.g. Spironolacton], loop diuretics) Methodically, this is will be investigated in particular by taking into account the patients history, standardized questionnaires and validated interviews.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Hannover, Germany, 30625
- Medical School of Hannover
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Treatment at Dept. of Gastroenterology, Hepatology and Endocrinology at Med. School of Hannover
- Liver cirrhosis
- Written consent for the use of personal data and health data for the purpose of this study
Exclusion Criteria:
- lack of written consent
- No consent ability
- Lack of literacy
- Inadequate knowledge of German language
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Norfloxacin
evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
|
questionaire, interview
|
Non-selective beta blockers
evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
|
questionaire, interview
|
diuretics
evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
|
questionaire, interview
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication adherence with BAASIS
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
Medication adherence will be investigated by using the BAASIS interview ((Basel Assessment of Adherence with Immunosuppressive Medication Scale)) The investigators use a validated German version of this instruments.
Adherence is classified by means of a reliable rating system.
For the BAASIS: Any YES on any of the questions 1a, 1B, 2 or 3 indicates an issue with implementation."YES"
on item 4 indicates non-persistence of medication use.
For the BAASIS the Overall can be quantified with both ways: as a dichtomus variable or as a continuous variable.
The dichotomous variable of the BAASIS will use the scores on the questions assessing implementation and persistence (Questions 1a, 1b, 2, 3 and 4).
The continuous variable will use a Visual Analogue Scale (VAS) assessing overall medication adherence over the last 4 weeks with higher scores represent higher perceived overall adherence.
|
One-point first visit, cross-section-designed study during the 24 month study period
|
Medication adherence with MARS
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
Medication adherence will be investigated by using the MARS ("Medication Adherence Report Scale" ) questionnaire (self-report). The investigators use a validated German version of this instruments. Adherence is classified by means of a reliable rating system. This 5-items scale asks respondents to rate the frequency with which they engage in each of 5 aspects of non-adherent behaviour Eg deciding to miss a dose, forgetting to take a dose), rated on a five point scale (where 5=never, 4 = rarely, 3 = sometimes, 2 = often and 1= very often). Scores for each of the 5 items were summed to give a scale score ranging from 5 to 25, where higher scores indicate higher levels of reported adherence. Adherence can be expressed as a continuous scale, or by separating into 'high' and 'low' adherence groups on the basis of scale scores. |
One-point first visit, cross-section-designed study during the 24 month study period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication satisfaction
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
Medication satisfactions is evaluated by using a self-report validated 19-item questionnaire ; the SIMS-D ("Satisfaction with Information about Medicines Scale").
Mediaction satisfaction is classified by means of a reliable rating system.
|
One-point first visit, cross-section-designed study during the 24 month study period
|
Medication belief
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
The investigators will use the "Beliefs about Medicines Questionnaire" (BMQ) as reliable survey tool for recording drug-related beliefs and perceptions of their benefits and / or harms.
For this projects the investigators will use most recent German version authored by Nestoriuc et al.
The BMQ is divided into a general and a drug-specific section.
Medication belief is classified by means of a reliable rating system.
|
One-point first visit, cross-section-designed study during the 24 month study period
|
Depression
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
Depression will be evaluated by another self-reported instrument, the "Patient Health Questionnaire" (PHQ 9), which is a screening tool for depression disorders with a sufficient reliability.
Depression is classified by means of a reliable rating system.
|
One-point first visit, cross-section-designed study during the 24 month study period
|
Anxiety
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
The investigators will use GAD 7 ("Generalized Anxiety Disorder Screeners"), another questionnaire, to screen for general anxiety disorders.
This refers to the last 2 weeks and covers the most important clinical criteria according to DSM-IV.
Anxiety is classified by means of a reliable rating system.
|
One-point first visit, cross-section-designed study during the 24 month study period
|
health-related Quality of Life
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
In addition, the investigators will use the CLDQ "Chronic Liver Disease Questionnaire" to examine the health-related quality of life in patients with hepatopathy regardless of severity or aetiology with high reliability.
HRQoL is classified by means of a reliable rating system.
The scale values of the subject are obtained by assigning 1 (always), 2 (mostly), 3 (common), 4 (repeated), 5 (sometimes), 6 (rare) and 7 (never)points.
The values of the subscales of the original version are obtained by adding the items of the respective scale on the CLDQ-D evaluation sheet.
The range of possible values per scale is between 1 and 7. Normative values of a representative population sample are not available.
For comparison, the results of clinical trials can be used.
Low values mean a reduced, high values a good health-related quality of life
|
One-point first visit, cross-section-designed study during the 24 month study period
|
Medication knowledge
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
At last, the investigators will evaluate the participant knowledge about their medication by using a self-constructed questionnaire.
For this purpose we constructed an own Rating System.
|
One-point first visit, cross-section-designed study during the 24 month study period
|
Sociodemographic data
Time Frame: One-point first visit, cross-section-designed study during the 24 month study period
|
Sociodemographic data (e.g.
age, education, income) will be collected with another self-constructed questionnaire in addition to already collected data of patients history from the disease record
|
One-point first visit, cross-section-designed study during the 24 month study period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Benjamin Maasoumy, Associate Professor, MD, Medical School of Hannover
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HannoverGAS-Adhaerenzprojekt
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medication Adherence
-
NYU Langone HealthRobert Wood Johnson Foundation; New York City Health and Hospitals CorporationCompletedMedication Adherence | Medication ErrorsUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingMedication Adherence | Medication ComplianceUnited States
-
Vanderbilt University Medical CenterCompletedAdherence, Medication | Nonadherence, MedicationUnited States
-
Universidad Autonoma de Baja CaliforniaCompletedMedication Adherence | Medication ComplianceMexico
-
Universiti Putra MalaysiaCompletedMedication Adherence | Adherence, TreatmentPakistan
-
University Hospital, Basel, SwitzerlandUniversity of BaselCompletedPolymedication-Check With Insight in Patients' Medication Organisation and Comprehension of GenericsMedication Adherence | Medication Therapy ManagementSwitzerland
-
Cliniques universitaires Saint-Luc- Université...RecruitingAdherence, MedicationBelgium
-
Northwell HealthNational Institute on Aging (NIA)RecruitingMedication AdherenceUnited States
-
Swedish Medical CenterNational Institute of Mental Health (NIMH); University of Washington; University...Recruiting
-
Northwell HealthToronto Dominion BankCompletedMedication AdherenceUnited States
Clinical Trials on questionaire, interview
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; University of ChicagoRecruitingBladder Cancer | Urothelial Cancer | Ureter Cancer | Renal Pelvis CancerUnited States
-
Sygehus LillebaeltKolding SygehusCompleted
-
University Hospital Inselspital, BerneCompletedSexual Orientation | Family CharacteristicsSwitzerland
-
Fayoum UniversityCompleted
-
The Cleveland ClinicUnknownSleep Apnea | Adverse EventUnited States
-
Hospices Civils de LyonCompletedAnoxic-Ischemic EncephalopathyFrance
-
Hillel Yaffe Medical CenterCompletedConditions Influencing Health StatusIsrael
-
Eurofertil IVF Health CenterCompletedStress | PregnancyTurkey
-
Zurich University of Applied SciencesCompleted